Searched for
PHARMACEUTICALS BUSINESS REVENUE
Zydus Lifesciences Q2 net profit falls 26.6% to Rs 925.5 croreZydus Lifesciences reported a net profit of ₹925.5 crore for the September quarter, which declined by 26.6%. The company's revenue from ope...- HRV Pharma buys Germany's PhateboThe acquisition marks virtual pharmaceutical company HRV's entry beyond active pharmaceutical ingredients (APIs) into finished formulations...
- Why is the US stock market split as Americans vote in the 2026 midterm elections today? Dow falls as S&P 500 and Nasdaq rise; Apple, Nvidia, and AMD in focus - gold and silver dipUS stock market today: US stocks opened mixed on Tuesday as Americans voted in the midterm elections. Investors are also waiting for AMD’s ...
- Emcure Pharma Q2 Results: Profit jumps 29% to Rs 325 croreEmcure Pharmaceuticals Ltd has posted a remarkable consolidated net profit of Rs 325.06 crore for the September quarter, reflecting substan...
- Emcure Pharma shares jump 7% after Q2 profit rises 29% YoY to Rs 325 croreEmcure Pharmaceuticals shares rose up to 7.3% after the company reported a 29.3% year-on-year increase in Q2 FY27 profit to Rs 325.1 crore....
- Stocks in news: ITC, Marico, SBI, Yatra Online, NSE, Container Corp and Sun PharmaIndian equity benchmarks experienced gains, with Nifty nearing the 23,500 resistance level and strong corporate earnings reported. ITC face...
- Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%Wockhardt has expanded its marketing access for Miqnaf in India following the removal of a supply condition. The company's biotechnology se...
- Mold-Tek Packaging shares surge 17% as Q2 FY 27 profit jumps 35% YoY to Rs 21 croreMold-Tek Packaging shares surged nearly 17% after the company reported a 35.5% YoY rise in Q2 FY27 net profit and 30.5% revenue growth. Str...
- Sun Pharma’s specialty portfolio, Organon deal to drive growthSun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines....
- Sun Pharma Q2 profit takes a hit on exceptional itemsSun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue ...
- Sun Pharma Q2 profit falls 36% as litigation costs hit earningsSun Pharma reported a 36% decline in Q2FY27 net profit to Rs 1,989 crore due to exceptional litigation and acquisition-related costs. Reven...
- Sun Pharma Q2 Results: Profit falls 36% YoY to Rs 1,989 crore on exceptional chargesSun Pharma Q2 Results: Revenue from operations rose 12% YoY to Rs 16,199 crore from Rs 14,478 crore in Q2 of last financial year, supported...
- Laurus Labs shares climb 4% after Q2 profit zooms 126% YoYLaurus Labs shares rose 3.79% to Rs 2,329 after the pharmaceutical company reported strong Q2FY27 results. Revenue increased 33% year-on-ye...
- Piramal Pharma cutting China exposure to manage supply-chain resilience, says Nandini PiramalIn a strategic move to enhance risk management, Piramal Pharma has drastically cut its reliance on Chinese raw materials to under 10%. The ...
- Cipla’s US recovery, biosimilar pipeline key to future growth prospectsCipla's September-quarter earnings suffered due to a high base in its US business. The company reported sequential growth driven by its str...
- Cipla Q2 net profit falls 35% to Rs 878 crore, revenue dips 2%Cipla reported a 35% year-on-year decline in second-quarter net profit to Rs 878 crore, with revenue and EBITDA also falling amid weaker No...
- Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore; revenue slips 2%Cipla reported a 35% drop in consolidated net profit for Q2FY27, which stood at Rs 878 crore. The company also experienced a 2.4% year-on-y...
- Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 croreMankind Pharma shares jumped nearly 8% after the company reported a 38% year-on-year rise in Q2 profit to Rs 716 crore. Revenue grew 17%, s...
- Mankind Pharma shares key business developments from Q2 & H1 of FY27The company outperformed the market by 1.1 times in both chronic and acute therapies. Cardiac and anti-diabetes brands registered growth of...
- Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginallyDr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America ...
Load More
